Most gastrointestinal stromal tumors(GISTs)are characterized by KIT or platelet-derived growth factor alpha(PDGFRA)activating mutations.However,there are still 10%-15%of GISTs lacking KIT and PDGFRA mutations,called wild-type GISTs(WT GISTs).Among these so-called WT GISTs,a small subset is associated with succinate dehydrogenase(SDH)deficiency,known as SDH-deficient GISTs.In addition,GISTs that occur in Carney triad and Carney-Stratakis syndromerepresent specific examples of SDH-deficient GISTs.SDH-deficient GISTs locate exclusively in the stomach,showing predilection for children and young adults with female preponderance.The tumor generally pursues an indolent course and exhibits primary resistance to imatinib therapy in most cases.Loss of succinate dehydrogenase subunit B expression and overexpression of insulin-like growth factor 1 receptor(IGF1R)are common features of SDH-deficient GISTs.In WT GISTs without succinate dehydrogenase activity,upregulation of hypoxia-inducible factor 1αmay lead to increased growth signaling through IGF1R and vascular endothelial growth factor receptor(VEGFR).As a result,IGF1R and VEGFR are promising to be the novel therapeutic targets of GISTs.This review will update the current knowledge on characteristics of SDH-deficient GISTs and further discuss the possible mechanisms of tumorigenesis and clinical management of SDH-deficient GISTs.
展开▼
